**Core Concept:** Her-2/neu is a proto-oncogene that, when amplified or overexpressed, contributes to tumorigenesis in breast cancer. It is a member of the epidermal growth factor receptor (EGFR) family and its activation leads to downstream signaling pathways that promote cell growth, survival, and angiogenesis.

**Why the Correct Answer is Right:** Her-2/neu amplification or overexpression leads to the activation of downstream signaling pathways involving the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK cascades. These pathways promote cell proliferation, survival, and angiogenesis, ultimately contributing to breast cancer progression.

**Why Each Wrong Option is Incorrect:**
A. Option A is incorrect because Her-2/neu amplification or overexpression is the driving mechanism for its oncogenic activity in breast cancer. Inhibition of Her-2/neu signaling may help in treating breast cancer.
B. Option B is incorrect because Her-2/neu is a proto-oncogene, not a tumor suppressor gene. Its amplification or overexpression leads to cancer progression, not prevention.
C. Option C is incorrect because Her-2/neu is a proto-oncogene, not a tumor suppressor gene. Its amplification or overexpression leads to cancer progression, not prevention.
D. Option D is incorrect because Her-2/neu amplification or overexpression doesn't lead to tumor regression or remission. Instead, it contributes to cancer progression.

**Clinical Pearl:** Understanding the role of Her-2/neu in breast cancer is crucial for selecting appropriate treatment strategies. Targeted therapies like Trastuzumab (Herceptin) and Trastuzumab emtansine (T-DM1) are used to target Her-2/neu overexpression in breast cancer treatment.

**Correct Answer:** C. Her-2/neu amplification or overexpression leads to cancer progression due to its oncogenic activity. Targeting Her-2/neu with therapies like Trastuzumab and Trastuzumab emtansine can help treat HER-2/neu positive breast cancers.